This is (supposed to be) a reflective diary by a (not very) anonymous biomedical scientist who works somewhere in the south of England.
One day this diary may well be submitted to the Health Professions Council as evidence of ongoing continual professional development....
This commentary discusses a recent report on the planning, implementation, and outcomes of a community-based colorectal cancer screening program in Shanghai, China, as well as important components of a successful cancer screening program.
Tomas G. Neilan, Mace L. Rothenberg, Laleh Amiri‐Kordestani, Ryan J. Sullivan, Richard M. Steingart, William Gregory, Subramanian Hariharan, Tarek A. Hammad, JoAnn Lindenfeld, Martin J. Murphy, Javid J. Moslehi, on behalf of the Checkpoint Inhibitor Safety Working Group
Immune checkpoint inhibitors are a class of drugs that trigger the immune system to recognize and fight cancer cells; however, related immune-related adverse events are a challenge. This commentary describes a workshop convened by Project Data Sphere to determine best approaches in the treatment of myocarditis, with the goal of minimizing the risk of this adverse reaction in patients with cancer who are treated with immune checkpoint inhibitors.
Recently, several cases of immune checkpoint inhibitor-related cardiotoxicity have been reported, with complications ranging from cardiogenic shock to sudden death. Clear guidelines for surveillance, diagnosis, and management of one such adverse event, myocarditis, are not currently available. This article describes a clinical vignette and discusses the salient features and management strategies for immune checkpoint inhibitor-associated myocarditis.
Mary Lou Affronti, Jennifer Gamboa Jackman, Frances McSherry, James E. Herndon II, Elwood C. Massey Jr., Eric Lipp, Annick Desjardins, Henry S. Friedman, Gordana Vlahovic, James Vredenburgh, Katherine B. Peters
Academia-Pharma Intersect: Symptom Management and Supportive Care
Chia‐Yu Chu, Jennifer Choi, Beth Eaby‐Sandy, Corey J. Langer, Mario E. Lacouture
Although seldom severe or life-threatening, dermatologic toxicities can result in physical and emotional discomfort for patients; therefore, appropriate management of such toxicities is important. This review provides oncologists with an understanding of dermatologic adverse events associated with the third-generation EGFR-TKI osimertinib.
This review provides clinicians with an overview of the available data on endocrine treatment in premenopausal women with hormone receptor positive metastatic breast cancer and summarizes the treatment options available in routine clinical practice.
Carmine Pinto, Maurizio Di Bisceglie, Francesca Di Fabio, Annamaria Bochicchio, Tiziana Latiano, Stefano Cordio, Gerardo Rosati, Carlo Aschele, Antonella Marino, Francesca Bergamo, Sara Bustreo, Luca Frassineti, Fortunato Ciardiello, Angela Damato, Stefania Giaquinta, Daniela Baldari, Luca Boni
This study evaluated the activity and safety of monoclonal antibody anti-EGFR panitumumab single agent without chemotherapy in low-risk LARC preoperative treatment. The use of anti-EGFR monoclonal antibodies in combination with radiotherapy in preoperative treatment in patients with KRAS wild type and low-risk LARC did not reach the pCR primary endpoint; however, this study showed a good toxicity profile and compliance to combination treatment.
This article reports the results of a randomized phase II study that investigated the efficacy and safety of CapIRI plus bevacizumab in relation to CapOX plus bevacizumab as a first-line treatment of metastatic colorectal cancer in Japanese patients.
Nina C.A. Vermeer, Yvette H.M. Claassen, Marloes G.M. Derks, Lene H. Iversen, Elizabeth van Eycken, Marianne G. Guren, Pawel Mroczkowski, Anna Martling, Robert Johansson, Tamara Vandendael, Arne Wibe, Bjorn Moller, Hans Lippert, Johanneke E.A. Portielje, Gerrit Jan Liefers, Koen C.M.J. Peeters, Cornelis J.H. van de Velde, Esther Bastiaannet
The aim of this international comparison was to compare treatment strategies and relative survival between countries for older patients with colon cancer, using data from population-based cancer registries across Europe.
Yangming Gong, Peng Peng, Pingping Bao, Weijian Zhong, Yan Shi, Kai Gu, Ying Zheng, Chunxiao Wu, Sanjun Cai, Ye Xu, Jun Sheng, Fan Wu
There is good evidence of the benefits of early detection of cancer and removal of adenomas in asymptomatic individuals; however, the widespread implementation of colorectal screening programs is resource-dependent. Such programs have been widely implemented in high-income regions and countries in North America, Europe, Japan, and South Korea, but such programs are few in low and middle-income countries . This article describes the implementation of a comprehensive approach to colorectal cancer screening in Shanghai, China.
Matteo Sarocchi, Francesco Grossi, Eleonora Arboscello, Andrea Bellodi, Carlo Genova, Maria Giovanna Dal Bello, Erika Rijavec, Giulia Barletta, Giovanni Rossi, Federica Biello, Giorgio Ghigliotti, Marco Canepa, Michele Mussap, Claudio Brunelli, Paolo Spallarossa
This article explores the potential role of seriated troponin assessments during treatment with nivolumab for advanced non-small cell lung cancer as a biomarker of nivolumab-related cardiac toxicity.
Loïc Chaigneau, Anna Patrikidou, Isabelle Ray‐Coquard, Thibaud Valentin, Claude Linassier, Jacques Olivier Bay, Laurence Moureau Zabotto, Emmanuelle Bompas, Sophie Piperno‐Neumann, Nicolas Penel, Thierry Alcindor, Maryline Laigre, Cecile Guillemet, Sebastien Salas, Anne Hugli, Julien Domont, Marie Pierre Sunyach, Axel Lecesne, Jean Yves Blay, Virginie Nerich, Nicolas Isambert
This article reports the results of a study conducted within the French Sarcoma Group. The natural history of sarcoma brain metastasis is described, and strategic recommendations are proposed for the management of patients with sarcoma brain metastasis.
Jai N. Patel, Lauren A. Wiebe, Henry M. Dunnenberger, Howard L. McLeod
Pharmacogenomics can guide clinicians to select the safest and most effective supportive medications for an individual cancer patient from the very first prescription. This review outlines a theoretical patient case and the implications of using pharmacogenetic test results to personalize supportive care throughout the cancer care continuum.
Evangelos K. Oikonomou, Sofia G. Athanasopoulou, Polydoros N. Kampaktsis, Damianos G. Kokkinidis, Christos A. Papanastasiou, Attila Feher, Richard M. Steingart, Kevin C. Oeffinger, Dipti Gupta
This article focuses on the challenge of maintaining cardiovascular health in long-term childhood cancer survivors. A simple risk score is proposed, which can be used in clinical practice to identify patients at increased cardiovascular risk.